Interpace Biosciences Current Ratio

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.